Physician-supervised program
2.4% placebo) 86.4% of participants lost at least 5% of body weight 69.1% lost at least 10% 50.5% lost at least 15% STEP 3 (Wadden et al., 2021, JAMA ): Combined with intensive behavioral therapy Average weight loss: 16.0% over 68 weeks Demonstrated that lifestyle support amplifies medication effects STEP 5 (Garvey et al., 2022, Nature Medicine ): Two-year duration study Average weight loss: 15.2% maintained over 104 weeks Demonstrated sustained effectiveness with continued use Retatrutide Clinical Trial Results Phase 2 Trial (Jastreboff et al., 2023, NEJM ): 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) Results at the 12 mg dose: Average weight loss: 24.2% in 48 weeks 100% of participants lost at least 5% of body weight 93% lost at least 10% 83% lost at least 15% 63% lost at least 20% Weight loss trajectory had not plateaued at study end Comprehensive Comparison Table Side Effects Comparison Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors
The proposal would require medical spas to register with the state, undergo inspections, designate a responsible licensed practitioner, and report serious adverse events, while tightening pharmacy compliance with federal standards
GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy
[1] Alternative Options When GLP-1 Treatment Fails When GLP-1 medications prove ineffective despite optimisation, several alternative therapeutic strategies exist, depending on whether the primary goal is diabetes management or weight loss
You should notice reduced appetite, some decrease in food noise (the constant background thinking about food), and potentially mild gastrointestinal adjustment
